Reviewing PAREXEL International (PRXL) & Its Competitors
PAREXEL International (NASDAQ: PRXL) is one of 199 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare PAREXEL International to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
This table compares PAREXEL International and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PAREXEL International Competitors||-3,961.82%||-118.13%||-43.77%|
Risk and Volatility
PAREXEL International has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, PAREXEL International’s rivals have a beta of 1.62, suggesting that their average stock price is 62% more volatile than the S&P 500.
Insider & Institutional Ownership
87.5% of PAREXEL International shares are held by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 2.9% of PAREXEL International shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings for PAREXEL International and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PAREXEL International Competitors||484||2289||6252||120||2.66|
PAREXEL International presently has a consensus price target of $74.46, indicating a potential downside of 15.47%. As a group, “Biotechnology & Medical Research” companies have a potential downside of 4.03%. Given PAREXEL International’s rivals stronger consensus rating and higher probable upside, analysts plainly believe PAREXEL International has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares PAREXEL International and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|PAREXEL International Competitors||$220.75||-$39.68||5.07|
PAREXEL International’s rivals have higher revenue, but lower earnings than PAREXEL International. PAREXEL International is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
PAREXEL International rivals beat PAREXEL International on 7 of the 11 factors compared.
PAREXEL International Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions.
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.